{"id":"W2910614206","doi":"10.1182/blood-2018-99-110465","title":"Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Myelodysplastic syndromes; Adverse effect; Neutropenia; International Prognostic Scoring System; Phases of clinical research; Gastroenterology; Febrile neutropenia; Hypomethylating agent; Clinical trial; Bone marrow; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002527744,0.001453835,0.002253186,0.0002721323,0.0005266746,0.0009518262,0.0007370411,0.001629936,0.003965866],"category_scores_gemma":[0.001848602,0.0007850912,0.001208302,0.0003314242,0.001210878,0.001096566,0.0004175727,0.003520375,0.00101989],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001115464,"about_ca_system_score_gemma":0.00100391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005814418,"about_ca_topic_score_gemma":0.001215537,"domain_scores_codex":[0.9991083,0.0004289296,0.00005710113,0.000211082,0.0000796828,0.0001149644],"domain_scores_gemma":[0.9985165,0.0002900783,0.0003077577,0.0001801776,0.0001055231,0.0005999376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8705496,0.06366856,0.006306901,0.0002471733,0.0009691422,0.0001132232,0.0002372335,0.00116426,0.02584743,0.00007221982,0.001159723,0.02966453],"study_design_scores_gemma":[0.4902852,0.4856602,0.01867775,0.0000162523,0.000569399,0.0001304937,0.00004708281,0.0006333755,0.002446889,0.0001204052,0.001378993,0.00003393322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961229,0.0007450067,0.000367381,0.0001687123,0.00008352089,0.001256331,0.0006066134,0.00004201016,0.0006076391],"genre_scores_gemma":[0.991525,0.0004835602,0.001020834,0.0006351447,0.0001607532,0.002141901,0.001889174,0.00002443395,0.002119225],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003965866,"threshold_uncertainty_score":0.01336813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02161170297583782,"score_gpt":0.3030744257456999,"score_spread":0.2814627227698621,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}